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Abstract: Parkinson’s disease (PD) is a neurodegenerative disease characterized by a progressive loss
of dopaminergic neurons from the nigrostriatal pathway, formation of Lewy bodies, and microgliosis.
During the past decades multiple cellular pathways have been associated with PD pathology
(i.e., oxidative stress, endosomal-lysosomal dysfunction, endoplasmic reticulum stress, and immune
response), yet disease-modifying treatments are not available. We have recently used genetic data
from familial and sporadic cases in an unbiased approach to build a molecular landscape for PD,
revealing lipids as central players in this disease. Here we extensively review the current knowledge
concerning the involvement of various subclasses of fatty acyls, glycerolipids, glycerophospholipids,
sphingolipids, sterols, and lipoproteins in PD pathogenesis. Our review corroborates a central
role for most lipid classes, but the available information is fragmented, not always reproducible,
and sometimes differs by sex, age or PD etiology of the patients. This hinders drawing firm
conclusions about causal or associative effects of dietary lipids or defects in specific steps of lipid
metabolism in PD. Future technological advances in lipidomics and additional systematic studies on
lipid species from PD patient material may improve this situation and lead to a better appreciation of
the significance of lipids for this devastating disease.
Keywords: Parkinson’s disease; fatty acyls; glycerolipids; glycerophospholipids; sphingolipids; sterol
lipids; lipoproteins; α-synuclein-mediated pathology; disease-modifying effects; neuroprotection
1. Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting 1% of
the population above 60 years and up to 4% of individuals in the highest age groups [1]. Parkinson’s
disease is characterized by motor symptoms, such us tremor, rigidity, bradykinesia (slowed movement)
and impaired balance [2], and non-motor manifestations, including sleep disorders, and autonomic,
gastrointestinal, sensory, and neuropsychiatric symptoms [3]. These symptoms are associated with a
progressive loss of dopaminergic (DA) neurons from the nigrostriatal pathway, formation of Lewy
bodies (LB), and microgliosis [4]. In familial PD, which explains 5–10% of all cases, these abnormalities
may be caused by a mutation in one of the thus far known 19 familial genes, including SNCA, LRRK2,
PRKN, PINK1 and DJ-1, among others [5]. The remaining 90–95% of PD cases are of sporadic nature
with unknown etiology.
Despite a large number of studies on familial forms of PD or toxin-induced cell and
animal PD models (e.g., use of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone or
6-hydroxydopamine (6-OHDA)) [6–8], no disease-modifying treatment for PD has been developed
yet. Thus, additional approaches are necessary to advance the field of PD. Previously, we used data
from genome-wide association studies and other genetic studies of PD patients to build a molecular
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landscape [9]. This enabled us to identify, in an unbiased way, various processes and pathways that
might be involved in PD. Interestingly, we found that lipids play a key role in most of the processes
that have been (classically) associated with PD (i.e., oxidative stress, endosomal-lysosomal function,
endoplasmic reticulum stress, and immune response), and thus in PD etiology. In agreement with this
observation, not only mutations in the gene encoding the lipid-producing enzyme glucocerebroside
(GBA) are associated with familial PD [10–12], but also multiple single-nucleotide polymorphisms
(SNPs) located in other genes involved in lipid metabolism, e.g., SREBF1 [13], DGKQ [14], ASAH1 [15]
or SMPD1 [16], have been linked to sporadic PD.
Lipids are biomolecules soluble in nonpolar organic solvents, usually insoluble in water,
and primarily known for their metabolic role in energy storage [17,18]. Furthermore, they
are the main constituents of cellular membranes, part of membrane rafts and protein anchors,
and signaling and transport molecules [19–23]. There are eight different classes of lipids, classified
as fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterols, prenols, saccharolipids,
and polyketides [24]. Here we will review the current knowledge of the role of the first five lipid
classes and of lipoproteins in PD (Figure 1). Certain aspects of the relationship between PD and
lipids are beyond the scope of this review, including the complex interaction between (membrane)
glycerophospholipids and α-synuclein, the interaction between lipid classes, and the role of cholesterol
derivatives, such as bile acids, tocopherols, and tocotrienols (vitamin E), vitamin A and carotenoids,
vitamin D, steroidal hormones (e.g., estrogen) and coenzyme Q10.
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Figure 1. Cellular lipid metabolism and lipoprotein cycle. Schematic representation of lipid 
metabolism, whereby each colored box represents one lipid class: (1) fatty acyls, which include 
saturated (SFA), monounsaturated (MUFA), and polyunsaturated (PUFA) fatty acids, their 
mitochondrial-transporter, acylcarnitine, and the PUFA-derivatives eicosanoids; (2) glycyerolipids, 
including monoacylglycerol (MAG), diacylglycerol (DAG), and triacylglycerol (TAG), together with 
endocannabinoids (even though only some of them belong to this lipid class); (3) phospholipids, 
which include phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylserine (PS), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylglycerol (PG), cardiolipin 
(CL), and their lyso derivatives (lysoPC (LPC), lysoPS (LPS), lysoPE (LPE), lysoPI (LPI), lysoPG (LPG) 
and lysoCL (LCL)), and Bis(monoacylglycero)phosphate (BMP); (4) sphingolipids, including 
ceramide(-1-phosphate), sphingosine(-1-phosphate), sphingomyelin (SM), cerebrosides, sulfatides, 
gangliosides, and globosides; (5) sterols, which include the metabolites of cholesterol synthesis, such 
as β-hydroxy β-methylglutaryl-CoA (HMG-CoA), cholesterol, and its derivatives cholesterol esters 
and oxysterols; and (6) lipoproteins, including high-density lipoproteins (HDL), intermediate-density 
lipoproteins (IDL), low-density lipoproteins (LDL), and very low-density lipoproteins (VLDL). A 
depiction of the various lipid structures and of all the metabolic steps involved in their generation 
and interconversion(s) is given in Figures 2a,b–6a,b, respectively. 
2. Fatty Acyls 
Fatty acyls are carboxylic acids formed by a hydrocarbon chain and a terminal carboxyl group 
(Figure 2) [25]. They are synthesized by chain elongation of acetyl-CoA with malonyl-CoA groups by 
1. e lular li i li cycle. Sche atic r r se tation
, whereby each c lored box presents one lipid class: (1) fatty acyls, which
include saturated (SFA), monounsaturated (MUFA), and polyunsaturated (PUFA) fatty acids, t i
it ri l-tr rt r, l r iti , t - ri ti i i ; ( ) l r li i ,
i cl i onoacylglycerol (MAG), diacylglycerol (DAG), and triac lglycerol (TAG), together
with e docannabinoids (even though only so e of them belong to this lipid class); (3)
phospholipids, which inclu e phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylserine
(PS), phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylglycerol (PG), cardiolipin
( L), and their lyso derivatives (lysoPC (LPC), lysoPS (LPS), lysoPE (LPE), lysoPI (LPI), lysoPG
(LPG) and lysoCL (LCL)), and Bis(monoacylglycero)phosphate (BMP); (4) sphingolipids, including
cera ide(-1-phosphate), sphingosine(-1-phosphate), sphingo yelin (S ), cerebrosides, sulfatides,
gangliosides, and globosides; (5) sterols, which include the metabolites of cholesterol synthesis, such as
β-hydroxy β-methylglutaryl-CoA (HMG-CoA), cholesterol, and its derivatives cholesterol esters and
oxysterols; and (6) lipoproteins, including high-density lipoproteins (HDL), intermediate-density
lipoproteins (IDL), low-density lipoproteins (LDL), and very low-density lipoproteins (VLDL).
A depiction of the various lipid structures and of all the metabolic steps involved in their generation
and interconversion(s) is given in Figures 2a,b–6a,b, respectively.
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2. Fatty Acyls
Fatty acyls are carboxylic acids formed by a hydrocarbon chain and a terminal carboxyl group
(Figure 2) [25]. They are synthesized by chain elongation of acetyl-CoA with malonyl-CoA groups
by enzymes named elongases. While humans can synthesize most fatty acyls, linoleic acid (LA)
and alpha-linoleic acid (ALA) need to be obtained through the diet [26]. Fatty acyls are not only
energy sources, but also the building blocks of complex lipids and as such form a key category
of metabolites. Additionally, they are membrane constituents and regulate intracellular signaling,
transcription factors, gene expression, bioactive lipid production, and inflammation [27,28]. Below,
we will discuss the current knowledge of the roles of fatty acyls, more specifically of saturated fatty
acids (SFA), monounsaturated fatty acids (MUFA), polyunsaturatedfatty acids (PUFA), eicosanoids
and (acyl)carnitine, in PD, and an overview can be found in Supplementary Materials Table S1.
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Figure 2. Fatty acyls: structures and metabolic steps involved. (a) Schematic representation of the 
chemical structures of fatty acyls, including saturated fatty acids (SFA 18:0), monounsaturated fatty 
acids (MUFA 18:1), omega-3 polyunsaturated fatty acids (PUFA, alpha-linoleic acid (ALA, top) and 
docosahexaenoic acid (DHA, bottom)), omega-6 PUFA (linoleic acid (LA, top) and arachidonic acid 
(AA, bottom)), eicosanoids (from left to right, prostaglandin E2 (PGL E2), leukotriene B4 (LT), 14,15-
Epoxyeicosatrienoic acid (EET), 15-F2t-Isoprostane (IsoP), and resolvin D2 (bottom)), and 
acetylcarnitine (AC 2:0) and acylcarnitine (AC 18:0). Chemical structures are adapted from the LIPID 
MAPS structure database [25]. (b) Schematic overview of steps involved in the metabolism of fatty 
acyls, where fatty acids (FAs) can be obtained through the diet or by a multi-enzymatic reaction 
starting from acetyl-CoA and performed by enzymes such as acetyl-CoA carboxylase 1 (ACACA) and 
fatty acid synthase (FASN). Multiple steps of elongation, performed by elongases, and desaturation, 
Fig re 2. Fatty acyls: structures and metabolic steps involved. (a) Schematic representation of
t e chemical structures of fatt acyls, including saturated fatty acids (SFA 18:0), mono nsaturated
fatty acids (MUFA 18:1), omega-3 poly nsaturated fatty acids (PUFA, alpha-linoleic acid (ALA, top)
and docos hexaenoic acid (DHA, bottom)), omega-6 PUFA (linoleic acid (LA, top) nd arachidonic
acid (AA, bottom)), eico anoids (from left to right, prostaglandin E2 (PGL E2), leukotriene B4
(LT), 14,15-Epoxyeicosatrienoic acid (EET), 15-F2t-Isoprostane (IsoP), and resolvin D2 (bottom)),
nd a etylcarnitine (AC 2:0) and acylcarnitine (AC 18:0). Chemical tructures are adapted from
the LIPID MAPS structure database [25]. (b) Schematic overview of steps involved in the metabolism
of fatty acyls, where fatty acids (FAs) can e obtained through the diet or by a multi-enzymatic r
, , t r ti ,
carried out by desaturases, produce MUFA and PUFA. PUFA include, among others, omega-3 PUFA,
such as ALA, which can be converted by a multistep reaction into eicosapentaenoic acid (EPA) and
DHA, and omega-6 PUFA, including LA, which can be transformed by a multistep reaction to AA. PUFA
can be further metabolized by enzymes such as lipoxygenase (LOX), prostaglandin-endoperoxide
synthase 2 (PTGS2, also known as COX2), cytochrome p450 2C to various eicosanoids, including
resolvins, PGL, LT, EET, or oxidized to isoP. Furthermore, transport of FA into mitochondria for their
metabolism is preceded by their association with carnitine, which is catalyzed by the enzyme carnitine
O-palmitoyltransferase 1 (CPT1) and reversed by carnitine O-palmitoyltransferase 2 (CPT2).
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2.1. SFA
The simplest fatty acids are the straight-chain SFA. Their intake does not seem to be linked to PD
risk in humans [29–31] per se, but SFA intake in individuals exposed to rotenone increases PD risk,
when compared to pesticide exposure alone [32]. Thus, SFA could exacerbate PD-linked pathology.
Interestingly, higher levels of SFA (mainly 16:0 and 18:0) have been observed in lipid rafts from the
frontal cortex of PD patients compared to controls [33], but not in their temporal cortex [34]. These
area-dependent changes combined with a lack of differences in SFA intake between PD patients and
controls point to defects in their absorption or metabolism and region-specific and/or cell-compartment
differences. Dietary supplementation with SFA 18:0, which seems to be a less potent pro-inflammatory
lipid than other SFA species [35], regulates mitochondrial function and rescues the PD-like phenotype
of PINK and PRKN mutant flies [36–38]. Similarly, both acute and repeated intra-gastric gavage
of SFA 8:0 reduces the impairment of DA neurotransmission in MPTP-treated mice [39]. These
findings, together with the observed higher SFA levels in the frontal cortical lipid rafts, may point
towards a compensatory mechanism in PD patients. In contrast, exposure of SH-SY5Y cells, primary
neurons, and astrocytes to SFA 16:0 leads to apoptosis, reduces peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PPARGC1A, PGC-1alpha) and estrogen receptor alpha (ER-alpha)
expression, promotes inflammation, and activates cyclooxygenase-2 (COX-2) [35,40–42], features that
have also been observed in the brains of PD patients [43–45]. Since α-synuclein modulates the uptake
of SFA 16:0 into the brain [46], accumulation of this protein in PD brains might lead to increased levels
of SFA 16:0, which in turn can trigger some of its neuropathological activities.
2.2. MUFA
Variants of SFA containing one double bond are known as MUFA. Higher MUFA intake has
been variably associated with decreased PD risk [31], reduced risk only in women [29] or unchanged
risk [30]. These discrepancies in findings could be due to variation in the ethnicity of the subjects,
differences in the type of study (cohort or case-control), the number of participants, questionnaires
employed to asses MUFA intake, the corrections used, or even PD etiology, since different MUFA levels
in cerebrospinal fluid (CSF) have been described in PD patients carrying a GBA mutation and those that
do not [47]. Of note, no abnormalities in MUFA level have been observed in the temporal cortex of PD
patients [34]. Some MUFA, such as oleic acid and cis-vaccenic acid, trigger the production of dopamine
in MN9D cells [48], and the amide of oleic acid and dopamine (N-oleoyl-dopamine) modulates the
firing of nigrostriatal DA neurons [49]. Interestingly, α-synuclein has a motif homologous to a region
in fatty acid-binding proteins, allowing it to bind to oleic acid [50], which facilitates the interaction
of α-synuclein with lipid rafts [51]. Based on these suggestive but still tentative findings, the effect
of MUFA intake on PD risk, and specifically, its effect on dopamine production and the intracellular
location and function of α-synuclein, should be further examined.
2.3. PUFA
Fatty acids containing two or more double bonds are known as PUFA and are usually classified
according to the position of the first double bond counted from the tail (omega). The omega-3 family,
for which ALA is the essential parent fatty acid, forms metabolic products that include eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA). Omega-6 PUFA, for which LA is the parent fatty acid,
include arachidonic acid (AA), an intensely studied precursor of signaling lipids [52]. In general,
PUFA are known to play a role in inflammation [53], epigenetics [54], and brain development [55]
and function [56]. As such, they have been widely examined in PD patients, and animal and cellular
PD models.
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2.3.1. Human Studies on PUFA
Higher intake of omega-3 PUFA and ALA, but not other PUFA, such as omega-6 PUFA or LA, has
been associated with reduced risk of PD [31,32], while other studies have reported a weak positive
association between omega-6 PUFA and LA intake and PD risk [57], or have provided evidence against
an association between PUFA intake and PD risk [30]. A link between AA intake and PD risk is
also controversial: one study described a positive association [30], while another reported an inverse
association [58]. Serum of PD patients has decreased concentrations of long-chain PUFA, including
ALA, LA, and AA, compared to controls [59], while the CSF of PD patients has increased levels of
4-hydroxynonenal, a toxic product generated by AA peroxidation [60]. However, as described for
MUFA, PUFA levels in CSF may depend on PD etiology [47]. The levels of PUFA in the anterior
cingulate cortex and the occipital cortex of PD patients are increased or not changed, respectively [61].
Additionally, the levels of DHA and AA are decreased in frontal cortex lipid rafts from PD patients [33],
while reduced LA, increased DHA and docosatetraenoic acid (an omega-6 PUFA), and no changes in
AA have been reported for the cytosolic fraction of PD frontal cortex [62]. Moreover, no changes of
PUFA were observed in the temporal cortex of PD patients [34]. Therefore, there is no agreement on
the impact of PUFA intake on PD risk and little information on PUFA levels in the blood, CSF and
brain of PD patients is available. The only consistent finding is the altered intracellular distribution of
PUFA in neurons from the frontal cortex of PD patients, i.e., reduced levels of DHA in the lipid rafts
and increased DHA in the cytosolic fraction.
2.3.2. Animal and Cellular Studies on PUFA
Omega-3 PUFA exert neuroprotective actions in MPTP-treated mice [63] by increasing the
expression of brain-derived neurotrophic factor [64] and have also neuroprotective activity in
6-OHDA-treated rats [65]. A decrease in the level of this class of PUFA has been observed in
the brains of an MPTP-induced goldfish PD model [66]. Furthermore, omega-3 PUFA deficiency
leads to a reduced ability of the nigrostriatal system to maintain homeostasis under oxidative
conditions, increasing the risk for PD [67]. Maternal omega-3 PUFA seem to partially protect a
lipopolysaccharide (LPS)-model for PD [68]. Likewise, the omega-3 PUFA DHA protects DA neurons
against MPTP–[69–71], paraquat—[72] or rotenone-induced toxicity [73] in rodent models and against
effects of 6-OHDA-treatment in Caenorhabditis elegans, mice and rats [74–76], also when administered
as TAG-DHA [77]. Moreover, DHA plays a crucial role in the differentiation of induced pluripotent
stem cells (iPSCs) into functional DA neurons [78] and DHA supplementation protects DA neurons
from the SN in MPTP-treated mice [79]. EPA and ethyl-EPA attenuate 1-methyl-4-phenylpyridinium
(MPP+)-induced cell death in SH-SY5Y cells, primary mesencephalic neurons, and brain slices [80,81],
and in vivo reduce MPTP/probecenid-induced dyskinesia and memory deficits (without preventing
nigrostriatal DA loss) [82]. Thus, omega-3 PUFA appear to have a neuroprotective role in animal
models for PD.
Additionally, pretreatment of rats with fish oil (which is rich in omega-3 PUFA) for 25 days before
6-OHDA treatment mitigates the loss of substantia nigra (SN) DA neurons [83]. In contrast, a chronic
supplementation of fish oil in rats does not protect DA neurons but increases dopamine turnover [84].
These differential effects could be explained by the finding that the ethyl ester of DHA, a PUFA
present in fish oil, enhances 6-OHDA-induced neuronal damage by triggering lipid peroxidation in
mouse striatum [85]. Lipid peroxidation, which occurs frequently in PUFA, may lead to mitochondrial
dysfunction [86] and α-synuclein oligomerization [87]. It is therefore not surprising that a number of
studies have demonstrated beneficial effects when using deuterium-reinforced (deuterated) PUFA
(which protects the PUFA sites susceptible for oxidation) [88–90], or PUFA in combination with
antioxidants [91]. Therefore, omega-3 PUFA, probably in combination with the prevention of lipid
peroxidation, should be further studied as a complementary therapy for PD.
Increased levels of omega-6 PUFA (LA and AA) have been reported in mice brain slices upon
MPP+ treatment [81]. Similarly, upregulated AA signaling has been observed in the caudate-putamen
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and frontal cortex of 6-OHDA-treated rats [92], and the striatum and midbrain of MPTP-treated
mice [93]. Both LA and AA are able to inhibit MPP+-induced toxicity in PC12 cells [94], while excess AA
aggravates α-synuclein oligomerization in PC12 cells [95]. Interestingly, a mouse model with impaired
incorporation of AA in the brain is resistant to MPTP treatment [96]. Hence, pharmacologically induced
PD is linked to an increase in AA, the consequences of which are at present unclear and could be
dose dependent.
2.3.3. Alpha-Synuclein and PUFA
Under physiological conditions, α-synuclein and PUFA are involved in endocytic mechanisms
linked to synaptic vesicle recycling upon neuronal stimulation [97]. Moreover, α-synuclein and PUFA
regulate each other, since α-synuclein increases endogenous levels of AA and DHA [62], and its
oligomers control the ability of AA to stimulate SNARE-complex formation and endocytosis [98].
Reciprocally, PUFA strongly interact with the N-terminal region of α-synuclein [99], enhancing its
oligomerization both in vivo and in vitro [100–102]. This might precede the formation of protective
(LB-like) inclusions in DA cells [103].
Studies on specific PUFA species have shown that DHA induces α-synuclein oligomerization [104]
by activating retinoic X receptor and PPAR-gamma 2 [105], effects that were prevented by
co-administering aspirin [106]. The oligomers formed in the presence of DHA seem to be cytotoxic [107]
and affect membrane integrity [108] and the physical properties of DHA itself (triggering formation of
lipid droplets) [109]. Alpha-synuclein aggregation is also induced by AA [110], but the oligomers that
are formed seem to be less toxic (more prone to disaggregation and enzymatic digestion) [111] and
their formation is prevented or enhanced by low or high doses of dopamine, respectively [112]. The
enhanced toxicity of dopamine might be related to its ability to form adducts with AA, which are able
to trigger apoptosis [113].
Interestingly, a diet poor in omega-3 PUFA (with or without DHA supplementation) did not affect
α-synuclein expression [114]. Accordingly, a DHA-rich diet had no effect on the DA system, motor
impairments or α-synuclein levels in α-synuclein-overexpressing mice but increased the longevity
of the mice [115]. This latter phenomenon might be related to the role of monomeric α-synuclein
in sequestering early DHA peroxidation products and thus reducing oxidative stress [116]. The
interaction between α-synuclein and (peroxidated) PUFA has recently been reviewed in more detail
elsewhere [87,117].
2.4. Eicosanoids and Docosanoids
Eicosanoids and docosanoids constitute a family of bioactive fatty acyls mainly generated by
AA, EPA, and DHA oxidation. They play a local role in infection and inflammation [118]. The family
includes PGL, LT, EET, isoprostanes, HETE, isofurans, and resolvins, among others. Interestingly,
one of the enzymes responsible for the formation of eicosanoids, COX-2, has been linked to PD
pathology. Its role in the disease has been reviewed elsewhere [119,120].
2.4.1. PGL
No changes in or increased PGL E2 levels have been observed in the CSF and SN of PD patients,
respectively [121,122]. In animal and cellular PD models, PGL E2 secretion is induced by LPS [123–125],
6-OHDA [126–128], rotenone [129,130], MPTP [131,132], and α-synuclein aggregation [133,134].
Nevertheless, PGL E2 levels in the striatum, hippocampus, and cortex of 6-OHDA-treated mice
are decreased following a four-week exposure [135]. The eicosanoid PGL E2 mainly mediates its
effects by binding to PGL E2 receptors (EP1-4), which trigger various intracellular pathways [136].
The EP1 receptor knock-out (KO) has neuroprotective effects on 6-OHDA-treated mice [137] and an
EP1 antagonist protects embryonic rat mesencephalic primary cultures from 6-OHDA toxicity [138].
An agonist of EP2 protects primary neuronal cultures from 6-OHDA-induced toxicity [139] and an
agonist of EP4 prevents DA loss in the SN of MPTP-treated mice [140]. Therefore, the effect of PGL
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E2 is also dependent on which receptor it binds. Interestingly, astrocytes KO for the familial PD gene
DJ-1 secrete less PGL E2 than WT astrocytes [141]. This could impair DA neuron survival mediated by
EP2 [142]. Thus, the sparse data that are available regarding the effects of PGL suggest that increased
PGL E2 levels may play a role in the pathology of animal and cellular PD models, but that this occurs
in a time-, location-, phenotype- and receptor-dependent manner.
Both PGL A1 and lipocalin-type PGL D synthase (the enzyme that isomerizes PGL H2 to
PGL D2) inhibit rotenone- and paraquat-induced apoptosis in SH-SY5Y cells, respectively [143,144].
Furthermore, enhanced prostacyclin synthesis seems to reduce glial activation and ameliorate motor
dysfunction in 6-OHDA-treated rats [145]. Conversely, PGL J2 treatment of SK-N-SH cells leads to the
formation of aggregates containing ubiquitinated α-synuclein [146], and infusion into the SN of mice
induces a pathology that mimics the slow-onset cellular and behavioral pathology of PD, including loss
of DA neurons in the SN, α-synuclein aggregation, posture impairment, and microgliosis [115,147,148].
Hence, PGL other than PGL E2 seem to play a role in PD pathology as well, with effects being protective
or detrimental. To resolve this complexity and obtain deeper insight into the contributions of these
oxidized PUFAs to PD pathology further research is needed.
2.4.2. LT
Increased plasma LT B3 has been suggested as a biomarker for PD [149]. However, the role of
LT has only been tested in animal and cellular PD models, in which MPTP treatment upregulates
arachidonate 5-lipoxygenase (5-LOX, the enzyme that synthesizes LT from AA). This work has
demonstrated that 5-LOX inhibition has neuroprotective effects [150], a finding which would be
in agreement with the observation that LT B4 enhances MPP+-induced neurotoxicity in midbrain
cultures [150]. Moreover, inhibition of cysteinyl LT receptor 1 has neuroprotective effects in a
rotenone-induced rat PD model [151,152]. Interestingly, 5-LOX KO in mice reduces striatal dopamine
levels under normal conditions [153]. Thus, 5-LOX seems to be necessary for maintaining the DA tone
but can become deleterious upon toxicant challenge.
2.4.3. EET
In PD patients, the SNP rs10889162 located in CYP2J2 (the enzyme that metabolizes AA into
EET) is associated with age of diagnosis [154]. Interestingly, EETs are known to have cytoprotective
effects in other diseases and may therefore also play a role in PD neuroinflammation [155]. In PD
models, 14,15-EET, which is released from astrocytes, enhances cell viability against oxidative
stress [156] and protects DA neuronal loss in MPTP-treated mice [157]. Inhibition or KO of the
soluble epoxide hydrolase (sEH, inhibition of which elevates endogenous EET) protects MPTP-treated
mice [157,158], and a double sEH and COX-2 inhibitor has protective effects on a rotenone-induced
Drosophila melanogaster PD model [159]. Combined, these findings suggest that EET has widespread
neuroprotective effects, not necessarily relevant for PD only.
2.4.4. Isoprostanes
The role of isoprostanes in PD is controversial. Both higher levels and no change in F2-isoprostane
have been found in urine and plasma [160–162] of (early) PD patients. Moreover, no changes have
been observed in CSF [163] or SN [164] of PD patients, but higher levels of F2-isoprostane have been
described in anterior cingulate cortex of PD patients [61]. Higher F2-isoprostane levels have also been
observed in rotenone-, but not manganese-treated DA neurons derived from healthy iPSC [165]. Thus,
more research and proper stratification of findings need to be performed to understand the role of
isoprostanes in PD.
2.4.5. Other Eicosanoids and Docosanoids
The classic and non-classic AA-derived eicosanoids, HETE and isofurans, are increased in
plasma [161,162] and SN [164] of PD patients, respectively. The docosanoid resolvin D1 attenuates
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MPP+-induced PD by inhibiting inflammation in PC12 cells [166], and resolvin D2 seems to restore
LPS-induced neural injury in a rat model, also by suppression of inflammation [167]. Thus, resolvins
seem to have a protective role in PD.
2.5. Carnitine and Acylcarnitine
Carnitine is a trimethyllysine derivative that can associate with various fatty acids, forming
acylcarnitine. This association facilitates their transport from the cytosol to the mitochondrial matrix,
where fatty acids undergo β-oxidation. Both carnitine and acylcarnitines are involved in processes
such as neurotransmission and apoptosis [168]. Decreased levels of carnitine and (long-chain)
acylcarnitines have been detected in plasma from PD patients [149,169,170], while no changes in
acylcarnitine levels have been found in either CSF or plasma from PD patients when compared to
controls [171]. Acetylcarnitine (acylcarnitine 2:0) protects SK-N-MC cells from rotenone-induced
toxicity [172], and carnitine reduces the effects of MPP+ on rat forebrain primary cultures [173] and
LPS in SIM-A9 microglial cells [174]. Moreover, the neuroprotective properties of acetylcarnitine have
been found in rats treated with 6-OHDA [175–177] and rotenone [178,179], and non-human primates
treated with MPTP [180]. Additionally, increased levels of carnitine and acylcarnitine 16:0 and 18:0
have been detected in the striatum of 6-OHDA-treated rats and the mesencephalon of MPTP-treated
mice, respectively [181,182], suggesting a compensatory mechanism against PD-associated toxicity.
Thus, while it remains unclear whether the levels of acylcarnitine change in PD patients, mounting
evidence points towards decreased plasma levels and a protective role of acylcarnitine in animal and
cellular PD models.
3. Glycerolipids
The esterification of one, two or three fatty acyls with glycerol gives rise to the glycerolipids
mono-, di-, and tri-substituted glycerol, known as monoacylglycerol (MAG), diacylglycerol (DAG),
and triacylglycerol (TAG), respectively (Figure 3). There is little information available on the function
of MAG, while DAG is a neutral lipid involved in the formation of membranes [55] and in the synaptic
vesicle cycle [183]. Additionally, DAG fulfills a role as secondary lipid messenger [184]. The neutral
lipid TAG is the main energy storage molecule [185]. Below, we will discuss the current knowledge of
the roles of all glycerolipids with potential significance for PD, including MAG, endocannabinoids,
DAG, and TAG, and an overview is given in Supplementary Materials Table S1.
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3.1. MAG
Decreased and increased expression of MAG lipase, the enzyme that degrades MAG to glycerol
and free fatty acids, has been observed in the SN and the putamen of PD patients, respectively [186].
These differential effects could be associated with the different mechanisms leading to the degeneration
of these brain areas; in PD patients, the SN presents with cell loss [187], while the putamen has DA
depletion [188]. In PD models, pharmacological inhibition of MAG lipase has neuroprotective effects in
both SH-SY5Y cells treated with MPP+ [189] and chronic MPTP/probenecid mouse models [190,191].
Although there is no information on the levels of MAG in PD patients, the model studies suggest that
MAG lipase inhibition, and thus higher levels of MAG, may be protective for PD.
Endocannabinoids
MAG include 2-arachidonoylglycerol (2-AG), which is classified as an endocannabinoid.
Endocannabinoids are a heterogeneous and thus difficult to classify group of lipids, including not only
2-AG, but also fatty acyl amides, such as anandamide (AEA). They have been previously linked to
PD [192].
Cells 2019, 8, 27 12 of 58
Two studies have reported high AEA levels in the CSF of untreated PD patients, which were
restored upon DA treatment [193,194]. Moreover, higher cannabinoid 1 receptor (CB1R) levels in the
putamen, and higher and lower cannabinoid 2 receptor (CB2R) levels have been reported in the SN
and putamen of PD patients, respectively [186]. Treatment of PD patients displaying no psychiatric
comorbidities with cannabidiol, a naturally occurring cannabinoid constituent of cannabis which
appears to lack psychoactive effects, improves quality of life measures, but does not improve Unified
Parkinson’s Disease Rating Scale scores [195]. The toxin 6-OHDA has been found to increase CB1R
mRNA expression [196], downregulate CB1R protein density in multiple brain regions [197,198] or not
produce any changes [199]. These differential effects may be explained by the fact that 6-OHDA seems
to change the expression of CB1R protein in a region- and time-specific manner [200]. Decreased CB1R
mRNA expression has been described in the striatum of reserpine-treated rats [201] and increased
CB1R protein density has been observed in PRKN KO female mice [202]. Moreover, CB1R agonists fail
to modulate spontaneous excitatory postsynaptic currents in cortical synapses of PINK1 KO mice [203],
which points towards a CB1R dysfunction in these synapses. Hence, there is no agreement on the
modulation of CB1R in different PD models and its correlation with the pathogenesis of PD in humans,
making further studies necessary.
Drug-induced animal PD models (using rotenone, 6-OHDA or LPS) show increased CB2R mRNA
expression [204,205], while a genetic model for PD (LRRK2 KO) does not display changes in CB2R
mRNA levels [206]. However, CB2R agonists appear to improve PD-linked impairments in both drug-
and genetically-induced rodent PD models [206–208]. Thus, CB2R upregulation in animal models may
reflect a compensatory mechanism, since the administration of CB2R agonists has positive effects on
PD-linked pathology.
Reduced levels of the AEA precursor synthesizing enzyme, N-acyl-transferase [209], and reduced
activities of the AEA membrane transporter and hydrolase [210,211] have been observed in the
striatum of 6-OHDA-treated rats. Moreover, 6-OHDA treatment has been found to both decrease [212]
and increase [210,211] striatal levels of AEA, while MPTP-lesions in monkeys increase striatal AEA
levels [213]. Interestingly, an increase of AEA levels, by inhibition of the fatty acid amide hydrolase
or administration of AM404 (an endogenous cannabinoid reuptake inhibitor), has neuroprotective
effects [209,210,214,215]. Hence, AEA seems to have neuroprotective effects, which have been
suggested to be mediated by activation of PI3K and inhibition of JNK signaling [216].
All MPTP, rotenone, and reserpine treatments lead to increased 2-AG levels in a time- and
region-specific manner in various animal PD models [213,217–219], and 2-AG administration provides
protection against MPTP-induced cell death [217]. The endocannabinoid N-arahidonoyl-dopamine has
anti-inflammatory effects on both macrophages and activated BV-2 cells [96] and modulates the activity
of SN neurons [220], together with the endocannabinoid-like N-oleoyl-dopamine [49]. This effect could
be linked to the fact that, together with an inhibitor of endocannabinoid degradation, administration
of a D2 receptor agonist improves motor performance in both a 6-OHDA-and a reserpine-model
for PD [221]. Similar to AEA, different members of the endocannabinoid group of lipids may thus
be neuroprotective.
3.2. DAG
Parkinson’s disease patients have decreased plasma levels of DAG [222,223], and increased DAG
levels in frontal cortex [224] and primary visual cortex [225]. Interestingly, SNPs from the chromosomal
region that includes the gene encoding diacylglycerol kinase theta (DGKQ), which mediates the
production of phosphatidic acid (PA) from DAG, are associated with PD susceptibility [14,226,227],
and DGKQ is linked to increased PA 36:2 production and consequent α-synuclein aggregation [228].
The dysregulation of integral DAG metabolism in PD patients could be related to the observed genetic
association between DGKQ and PD.
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3.3. TAG
TAG levels are decreased in serum and plasma of (male) PD patients [222,223,229–233], even
before diagnosis [234], and higher serum TAG is associated with reduced risk of idiopathic
PD [235]. However, other studies have found no differences in blood TAG levels of PD patients and
controls [236,237]. In the primary visual cortex of PD patients, the levels of TAG are decreased [225].
Thus, reduced levels of TAG seem to be linked to PD, although high heterogeneity has been described
for TAG in PD patients [238]. Gender, ethnicity, or the technique used to measure TAG could bias
the obtained results and contribute to the observed heterogeneity. Nevertheless, the trend from the
majority of the results is in line with findings in animal models for PD, in which α-synuclein A53T
overexpression leads to deceased serum TAG levels [239], and 6-OHDA treatment decreases TAG
levels in retroperitoneal white adipose tissue [240]. Both rotenone and α-synuclein overexpression
have been linked to intracellular deposition of TAG [241,242], which forms lipid droplets to which
α-synuclein binds, and as such, the turnover of stored TAG is reduced and α-synuclein aggregation
is enhanced [243]. In agreement, α-synuclein A53T overexpression in N27 cells leads to increased
intracellular levels of TAG [244]. Thus, intracellular deposition and reduced turnover of TAG may
explain the reduced levels of this acylglycerol in PD serum. Interestingly, Saccharomyces cereviciae that
are unable to synthesize TAG are more tolerant to α-synuclein overexpression [242].
4. Glycerophospholipids
Glycerophospholipids, or phospholipids, have a glycerol backbone and a polar head group,
which allows their classification into distinct subgroups, known as PA, phosphatidylethanolamine (PE),
phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidyllycerol
(PG) and cardiolipin (CL) (Figure 4). The hydrolysis of one acyl derivative gives rise to the
lipid species known as lysophospholipids. Glycerophospholipids are key components of the
lipid bilayers of cells, and as such play a role in organelle function [245] and processes like
endocytosis [246] or mitophagy [247]. Moreover, they also act as signaling molecules [248–250] and
regulate lipid metabolism-related gene expression [251]. Below, we will discuss the current research
on glycerophospholipids in PD, more specifically PA, PE, PS, PC, PI, PG and CL, and an overview is
given in Supplementary Materials Table S1.
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Figure 4. Phospholipids: structures and metabolic steps involved. (a) Schematic
representation of the chemical structures of phospholipids, including phosphatidic acid
(PA 16:0/14:0), phosphatidylethanolamine (PE 16:0/14:0), phosphatidylserine (PS 16:0/14:0),
phosphatidylcholine (PC 16:0/14:0), phosphatidylinositol (PI 16:0/14:0), phosphatidylglycerol
(PG 16:0/14:0), and cardiolipin (CL 16:0/16:0/16:0/16:0). Chemical structures are adapted
from the LIPID MAPS structure database [25]. (b) Schematic overview of phospholipid
metabolism. Synthesis starts with the conversion of fatty acids into lysophosphatidic acid
(LPA) by glycerol-3-ph sph e cyltransferase (GPAT). LPA is then metabolized to PA by
1-acyl-sn-glycerol-3-phosphate acyltransfera e 1-5 (AGPAT1-5), a reaction that can e reversed by
phospholipase A2 (PLA2). PA can then be metabolized to diacylglycerol (DAG) (process described
in Figure 3b), which can be subsequently transformed to PE by ethanolaminephosphotransferase
1 (SELENOI) or PC by cholinephosphotransferase 1 (CHPT1). PE can also be converted into
PC by the enzyme phosphatidylethanolamine N-methyltransferase (PEMT). Both compounds
can be precursors for the synthesis of PS by the enzymes phosphatidylserine synthase1/2
(PTDSS1/2). The conversion of PE to PS can be reversed by phosphatidylserine decarboxylase
proenzyme (PISD). Additionally, PA can be metabolized by phosphatidate cytidylyltransferase
1/2 (CDS1/2) to cytidine diphosphate DAG (CDP-DAG), which can then be transformed
to either PI, PG or CL, by CDP-diacylglycerol–inositol 3-phosphatidyltransferase (CDIPT),
CDP-diacylglycerol–glycerol-3-phosphate 3-phosphatidyltransferase (PGS1) and cardiolipin synthase
(CRLS1), respectively. PI can be phosphorylated by PI (phosphate) kinases (PI(P)K), to produce PI
phosphate (PIP(x)). Moreover, all phospholipids can be metabolized to their lyso-forms (LPC, LPS,
LPE, LPI, LPG, and LCL) by PLA2, a reaction reversed by lysophospholipid acyltransferases (LPCATs).
LPG can be further metabolized to Bis(monoacylglycero)phosphate (BMP).
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4.1. PA
One of the best-known glycerophospholipid messengers is PA, which has a broad spectrum of
functions, including intracellular vesicular trafficking, cell survival, cytoskeletal organization, neuronal
development, and mitochondrial function [252–254]. Increased plasma PA (18:2/15:0) levels have
been suggested as a biomarker for PD [149]. Additionally, PA is known to interact with residues
1–102 of α-synuclein [255,256], thus enhancing the formation of multimeric and protease-resistant
α-synuclein aggregates [257,258]. ATP13A2, a lysosomal ATPase, which, when mutated, causes
familial PD, constitutes another link between PA and PD. This ATPase requires the interaction with PA,
and also PI(3,5)P2, to protect cells against rotenone-induced mitochondrial stress or other PD-related
stress conditions, such as exposure to Fe(3+) [259,260]. Furthermore, overexpression of phospholipase
D2 appears to induce DA neuronal cell loss via a mechanism involving PA signaling [261]. Given
PA’s role in the subcellular distribution and aggregation of α-synuclein, and in ATP13A2-mediated
neuroprotection, it would be of interest to study PA levels and its partitioning in the brains of
PD patients.
LPA
Similar to PA, LPA is a lipid mediator in a wide range of biological actions, including cell
proliferation, (nervous system) development, and cytokine secretion [262–264]. Furthermore, LPA is
involved in neuronal (DA) differentiation [265]. The expression of LPA receptor 1 is reduced in the
SN of a 6-OHDA rat PD model [265], and an LPA receptor ligand attenuates the MPTP mouse PD
model [266]. Unfortunately, nothing is known about LPA in PD patients.
4.2. PE
The glycerophospholipid PE has a structural role in biological membranes, and it is a regulator
of cell division, membrane fusion/fission, and hepatic secretion of very low-density lipoproteins
(VLDL) [267]. Patients with PD show decreased plasma levels of PE 34:2 [222], and those carrying
a GBA mutation have decreased serum levels of PE compared to non-GBA mutation carriers [268].
Decreased total PE levels have also been observed in the SN of PD patients before treatment [269],
in males only after treatment [270], and in the primary visual cortex [225]. In contrast, increased PE
has been found in frontal cortex lipid rafts from PD patients [33]. Of note, one of the enzymes linked
to PE synthesis, phosphoethanolamine cytidylyltransferase, is elevated in the SN of PD patients [271].
All findings combined, most evidence points towards decreased levels of PE in PD patients, but the
biological implications of the reduced levels need to be examined further.
In vitro, PE is necessary for the interaction between α-synuclein and biological membranes [272]
and for the formation of stable, highly conductive channels by α-synuclein [273]. Both processes
might have a role in the normal function of α-synuclein. Accordingly, in yeast and worm models, PE
deficiency disrupts α-synuclein homeostasis and induces its aggregation [274,275]. This deficiency,
also seen in PD patients, could be due to increased formation of LPC from PE, which occurs in MPP+
models [276]. Moreover, the inhibition of this metabolic step offers significant protection against
cytotoxicity [277].
4.3. PS
The glycerophospholipid PE is involved in the triggering of both intracellular and extracellular
cascades, such as the activation of kinases or the clearance of apoptotic cells [250,278]. It plays a role
in neuronal survival and differentiation, and neurotransmitter release [279]. Plasma levels of PS 40:4
are decreased in PD patients [222], but higher levels of PS 36:1, PS 36:1, 36:2, and 38:3, or overall
PS, have been found in parkin-mutant fibroblasts [280], frontal cortex [224], and primary visual
cortex [225] of PD patients, respectively. This is in agreement with the increased PS synthase activity
that has been observed in the SN of PD patients [271]. However, some groups reported contrasting
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findings and claimed that total PS levels in PD SN and frontal cortex lipid rafts are not significantly
altered [33,270]. Yet another interesting finding is that parkin-mutant iPSC-derived neurons have a
different subcellular distribution of PS [281], with increased and decreased PS in the mitochondrial
and ER fractions, respectively.
The exposure of PS on the cellular surface, which acts as an “eat-me” signal for phagocytosis,
is triggered by 6-OHDA [282], rotenone [283], paraquat [284], MPP+ [285], and WT, A53T and
A30P α-synuclein [286]. Blockade by an antibody against PS is protective in a rotenone-induced
neuronal/glial PD model [287], pointing towards a role of microglial-mediated phagocytosis
in PD. This glyceroplipid is known to be associated with the N-terminal- and mid-region of
α-synuclein [256,288], with some preference for acetylated α-synuclein [289,290]. This association
correlates with membrane penetration [255], alpha-helix formation [256] and aggregation [291],
and vesicle [256,292] and liposome [51] binding. Taken together, these findings suggest that PS
is a modulator of apoptosis and α-synuclein-mediated pathology.
4.4. PC
The most-abundant glycerophospholipid in eukaryotic membranes, including mitochondrial
membranes [293], where it plays a structural role, is PC. It is involved in anti-inflammation [294],
cholesterol metabolism [295], and neuronal differentiation [296]. Decreased levels of PC 34:2 and
46:2, PC 34:5, 36:5, and 38:5, and total PC, have been observed in plasma and frontal cortex
from PD patients [222,224], and in SN from only male PD patients [270], respectively. One of the
enzymes involved in PC synthesis, PC cytidylyltransferase, is elevated in the SN of PD patients [271].
Interestingly, components of the pathway “PC biosynthesis”, together with “PPAR signaling”
components, allowed accurate classification of PD and control samples [297], highlighting altered PC
metabolism as a consistent feature of PD.
Decreased PC levels have been found in the SN of a mouse model of early PD [298] and in brain
tissue from MPTP-treated goldfish [66]. Interestingly, α-synuclein does not bind to but rather remodels
pure PC membranes through weak interactions with this phospholipid [299,300], and α-synuclein
E46K mutants form functionally distinct ion channels in PC membranes [301]. However, others
observed binding of the physiologically relevant N-terminally acetylated α-synuclein to pure PC
membranes, with preference for highly curved and ordered membranes [302]. Based on these multiple
links, the significance of PC metabolism for PD pathology is an interesting and important topic for
further study.
LPC
The most-abundant lysophospholipid in the blood is LPC. Its levels are critically related to major
alterations in mitochondrial function (e.g., oxidation rate) and to minor defects in mitochondrial
permeability [303,304]. Of note, saturated acyl LPCs have inflammatory properties, such as
leukocyte extravasation and formation of pro-inflammatory mediators, which can be compensated by
polyunsaturated acyl LPC, such as LPC 20:4 and LPC 22:6 [305]. Higher levels of LPC 16:0 and 18:1
have been found in the lipid profile of parkin-mutant fibroblasts compared to healthy controls [280].
Moreover, increased plasma LPC 18:2 has been suggested as a biomarker for PD [149].
Treatment with MPTP induces LPC formation, which leads to cytotoxic changes, dopamine release
and inhibition of its uptake, a decreased mitochondrial potential, and increased reactive oxygen species
(ROS) formation in PC12 cells [277]. The lysophospholipid LPC inhibits D1 and D2 receptor binding
activities in the striatum of rats, inhibits the dopamine transporter, and decreases striatal dopamine
turnover rate [306], leading to hypokinesia [307]. Interestingly, 6-OHDA treatment of rats gives rise to
an overall decrease in LPC species, with the exception of LPC 16:0 and 18:1, which are increased in
the SN [298]. Thus, LPC has negative effects on the DA system, but LPC levels in PD models seem to
depend on the type of pharmacological treatment used and the LPC species involved.
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4.5. PI
The glycerophospholipids PI and PI phosphates are part of intracellular signal transduction
systems [308], but relatively little is known about their role in PD. In humans, higher levels of PI 34:1
and no changes of PI 36:1, 36:2, 38:4, 38:5, 40:5, and 40:6, or no changes in total PI have been observed
in parkin-mutant skin fibroblasts [280], and in the lipid rafts of frontal cortex from PD patients [33],
respectively. Decreased levels of overall PI have been observed in the SN of male PD patients [270].
In rodents, MPTP decreases the expression level of striatal PI-transfer protein [309], which is involved
in the transfer of PI across membranes [310].
PI Phosphate (PIPx)
The role of PIPx species in PD is also poorly defined. However, PI and PIP2 effectively influence
self-oligomerization of α-synuclein [311], while α-synuclein seems to prefer binding membranes
containing PI(4,5)P2 [312]. Moreover, PIP3 is decreased in the nuclear fraction and whole-tissue
homogenate, while PIP2 is increased in whole-tissue homogenate of SN from PD patients [313].
As mentioned above, ATP13A2 requires the interaction with PI(3,5)P2 to protect cells against PD-related
stress conditions [259,260], an interaction that is able to reduce proteasomal inhibitor-induced
accumulation of ubiquitin proteins [314]. Future systematic studies on the roles of the various PIPx
species are required to understand their function in PD pathogenesis.
4.6. PG
Less than 1% of total glycerophospholipids in intracellular membranes is composed of PG and
it is mainly localized to mitochondrial membranes, where it can be synthesized locally [315]. The
levels of total PG are not changed in lipid rafts from PD frontal cortex [33], while increased PG 32:0
has been described in total extracts of the same brain area [224]. Alpha-synuclein is able to bind
PG with various degrees of affinity depending on the variability in its structure (WT ≈ truncated >
A53T > A30P) [316], and PG-containing membranes can promote α-synuclein aggregation [317–319].
Additionally, α-synuclein oligomers are able to induce PG clustering [319], connect PG-containing
vesicles [320] and disrupt PG vesicles [321] through large membrane bilayer defects, rather than
through a pore-like mechanism [322], leading to vesicle docking and fusion problems. Furthermore,
low concentrations of α-synuclein inhibit and high concentrations stimulate lipid peroxidation of
PG [323]. Unfortunately, information on the levels of PG in animal PD models is lacking.
4.7. CL
The glycerophospholipid specific for mitochondrial membranes is CL. Here, it plays both a
structural and functional role [324–326]. No changes in total CL levels have been detected in the SN
of PD patients [270]. However, PINK1 KO mouse embryonic fibroblasts display decreased CL levels
and supplementation with CL rescues mitochondrial dysfunction [327]. Moreover, rotenone induces
oxidation of highly unsaturated CL in human peripheral blood lymphocytes [328], and increases
levels of plasma PUFA CLs, but decreases oxidizable PUFA-containing CL levels and increases
mono-oxygenated CL species in the SN of rats [329]. A proper CL content in the inner mitochondrial
membrane and the presence of acyl side chains are crucial for α-synuclein localization [330,331],
while CL content in the outer mitochondrial membrane buffers synucleinopathy [332]. Moreover,
α-synuclein is able to disrupt artificial membranes containing CL [333], and its overexpression reduces
CL content in MN9D cells [334] and in mouse brain [335]. Additionally, the formation of complexes
between CL and α-synuclein, together with cytochrome c, may be a source of oxidative stress [336].
The role that CL plays in the interaction of α-synuclein with membranes and in mitophagy has been
previously reviewed [337,338].
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5. Sphingolipids
Sphingolipids constitute a family of lipids characterized by the presence of a sphingoid-base
backbone. This complex family of compounds includes the sphingoid bases (e.g., sphingosine
and sphingosine-1-phosphate), ceramides, phosphosphingolipids (e.g., sphingomyelin (SM)) and
glycosphingolipids (e.g., cerebrosides, ganglisodes, and sulfatides) (Figure 5). Sphingolipids
are not only structural components of cell membranes, but they also play a role in apoptosis,
autophagy, and immune response [339]. Here, we will specifically focus on the involvement of
sphingosine(-1-phosphate), ceramide, SM, cerebrosides, gangliosides, and sulfatides, and an overview
is given in Supplementary Materials Table S1.
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ultistep process to convert fatty acids (F s) into cera ide. Phosphatidylcholine can be fused to
cera ide by phosphatidylcholine:ceramide cholinephosphotransferase 1/2 (SGMS1/2) to produce SM,
which can be converted back into ceramide by sphingomyelin phosphodiesterase (SMPD1). Ceramide
can also be phosphorylated by ceramide kinase (CERK) to ceramide-1-P and converted into sphingosine
by acid or alkaline ceramidases (ASAH1/2 or ACER1-3), and phosphorylated by sphingosine kinase
1/2 (SPHK1/2) to sphingosine-1-phos ate. This process can be reversed by the sequential action of
sphingosine-1-ph sphate phosphatase 1/2 (SGPP1/2) nd ceramide synthase 1 (CERS1). Furthermore,
ceramide can be glycosylated via the addition of a galactos molecule by 2-hydr xyacylsphingosine
1-beta-g lactosyltran ferase (UGT8) to pr duce galacto ylceramide (GalCer). F rther addi ion of a sulfate
group by galactosylceramide sulfotransferase (GAL3ST1) results in th formation of sulfatides. This
proce s can be reversed by the sequential actions of arylsulfatase A (ARSA) and galactocerebr sidase
(GALC). Finally, ceramide can also by glycosylat d via the addition of glucose molecule b ceramide
glucosyltransferase (UGCG) to produce GlcCer, which can be further glycosylated to produce both
globosides and gangliosides, such as GM3, GD2 and GT1, by multiple enzyme [340], or it can be
converted back into c ramid by gluc syl eramidase (GBA).
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5.1. Sphingosine(-1-Phosphate)
Sphingosine is a bioactive lipid known to induce apoptosis and regulate endocytosis, while its
phosphorylated form, sphingosine-1-phosphate (S1P), promotes cell survival and triggers diverse
intracellular signaling pathways through G-protein-coupled receptors [339,341,342]. Sphingosine
induces the formation of oligomeric α-synuclein species, which serve as template for the formation
of endogenous α-synuclein aggregates in human and mammalian neurons [343]. Similarly, S1P
accumulation, e.g., due to GBA deficiency, promotes α-synuclein aggregation [343]. Alpha-synuclein
itself inhibits the expression and activity of sphingosine kinase 1, the enzyme that catalyzes the
phosphorylation of sphingosine to S1P [344] and modulates S1P receptor-mediated signaling [345,346].
Sphingosine-1-phosphate supplementation of MPP+-treated cells is neuroprotective [347–349], and a
selective S1P receptor agonist is protective in mouse and cellular models treated with 6-OHDA and
rotenone [350]. Therefore, while S1P is protective in animal and cellular PD models, presumably
through its pro-survival effects, it is clear that both sphingosine and S1P are linked to α-synuclein
aggregation. Unfortunately, the lack of studies on human samples does not allow drawing a conclusion
regarding the relevance of these lipids for PD pathogenesis.
5.2. Ceramide
Ceramide is involved in apoptosis, lipid raft formation, and regulation of the mitochondrial
respiratory chain [340,351–353]. Both higher [354] and lower [222,355] plasma levels of ceramide have
been reported in PD patients, while lower ceramide 18:0 and no differences in total ceramide levels are
observed in their frontal cortex [224] and SN [270], respectively. Reduced levels of ceramide may be
associated with α-synuclein accumulation [356,357]. This is in line with the finding that reduced and
increased levels of ceramide have been observed in the anterior cingulate cortex and primary visual
cortex of PD patients [225,356,358], which display and lack α-synuclein aggregation, respectively [359].
Thus, variation in the levels of ceramide in different tissues may be linked to α-synuclein accumulation.
Mimicking PD with PLA2G6 KO, LRRK2 KO, PINK1 KO or rotenone treatment increases ceramide
levels in fly brain, mouse brain, mouse olfactory bulb, and human erythrocytes, respectively [283,360–362].
C2-ceramide initiates a series of events leading to neuronal death, including an early inactivation of
PI3K/AKT and ERK pathways, followed by activation of JNK, GSK3β activation and neuronal death [363].
Additionally, C2-ceramide induces cytotoxicity and ROS production in neuronal(-like) cells [364–366],
which can be prevented by WT α-synuclein [367], PINK1 [368,369] and DJ-1 [370]. However, both
in vivo and in vitro C2-ceramide seems to suppress microglial activation [371], protect neurons against
α-synuclein-induced cell injury [372], and reverse rotenone-induced phosphorylation and aggregation of
α-synuclein [373]. An increase in ceramide levels is thus commonly found in animal and cellular models
for PD, but its effects are unclear and may be both beneficial and detrimental for different PD-related traits.
5.3. SM
The most abundant sphingolipid in eukaryotic cells and plasma is SM. It is one of the
building blocks of the cellular membrane and a source of bioactive lipids, such as ceramide,
ceramide-1-phosphate and S1P, which are involved in inflammation [374,375], cell death [376,377]
and autophagy [378]. In the nervous system, SM is a major constituent of myelin. Mutations in
sphingomyelinase-1, which lead to SM accumulation, are a risk factor for PD [16,379,380]. This feature
may be linked to the increase in α-synuclein expression observed upon SM treatment [381] and the
presence of SM in LB inclusions [382]. Parkinson’s disease patients carrying GBA mutations have
elevated levels of total plasma SM compared to PD patients not carrying the mutation [268]. Moreover,
SM 18:1 and SM 26:1 are increased and decreased in the anterior cingulate cortex [358], respectively,
while increased SM levels have been described in the primary visual cortex [225], and, in males only,
in the SN of PD patients [270]. However, no changes have been found in the putamen or cerebellum
of sporadic PD patients [383]. The role that SM accumulation appears to play in PD pathogenesis
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may thus be multifold, being linked to inflammation, autophagy dysfunction, and/or α-synuclein
expression and aggregation.
5.4. Cerebrosides
Cerebrosides are lipids glycosylated via the addition of either glucose or galactose and known to
be involved in intracellular membrane transport and cell survival [384]. In PD patients, cerebrosides
are increased in plasma (of GBA mutation carriers) and, in males only, in the SN, whereas they are
decreased in lipid rafts from the frontal cortex [33,268,270,385]. More specifically, PD patients have
increased levels of glucosylceramide [223,354] in plasma but no changes in cerebroside levels in the
temporal cortex [386], putamen or cerebellum [383], and decreased levels of galactosylceramide 24:1
and lactosylceramide 18:1 in the frontal cortex [224]. Thus, whereas a consistent coupling between
PD and increased cerebrosides in plasma has been found, cerebroside changes in the brain are region
dependent and their significance for PD needs to be determined.
Interestingly, mutations in the enzymes responsible for the degradation of cerebrosoides,
namely GBA and galactocerebosides (GALC), which cause Gaucher’s disease and Krabbe’s disease,
respectively, have been associated with α-synuclein aggregation and PD [387,388]. Glucosylceramide,
a product that accumulates upon GBA deficiency, destabilizes α-synuclein tetramers and related
multimers and frees α-synuclein monomers and leads to cellular toxicity [389]. These effects are caused
by colocalization of glucosylceramide with α-synuclein and induction of a pathogenic conformational
change of the protein [390]. This promotes aggregation of WT (but not mutated) α-synuclein into a
β-sheeted conformation [343,391], and conversion of α-synuclein into a proteinase-resistant form [392].
Conversely, α-synuclein inhibits normal activity of GBA [393], which increases glucosylceramide,
creating a feedback loop. Inhibition of glucosylceramide synthase, which decreases glucosylceramide
levels, slows α-synuclein accumulation [394] and partially protects mice against MPTP-induced
toxicity [395]. Thus, it is well established that glucosylceramide accumulation leads to α-synuclein
aggregation and toxicity. Interestingly, aging of WT mice leads to brain accumulation of both
glucosylceramide and lactosylceramide [396], suggesting that age-associated changes in its metabolism
might be related to PD onset.
5.5. Gangliosides
Gangliosides are synthesized by the addition of carbohydrate moieties to lactosylceramide. One
of the simplest and most widely distributed ganglioside is monosialodihexosylganglioside (GM3)
that consists of lactosylceramide and sialic acid [397]. Gangliosides were initially discovered in
the brain where they are involved in neurotransmission, receptor regulation, and stabilization of
neural circuits, including the nigro-striatal DA pathway [398,399]. Parkinson’s disease patients have
higher plasma levels of gangliosides [385], GM3 gangliosides [223], and N-acetylneuraminic acid-3
(NANA-3) gangliosides [222] than controls. Likewise, higher GM2 and GM3 levels have been detected
in parkin-mutant iPSCs compared to controls [280]. However, no accumulation of GM1, GM2 or GM3
has been observed in the putamen or cerebellum of sporadic (or heterozygous GBA-mutation) PD
patients [383], nor in the SN of PD patients [270]. Even a GM1 deficiency, together with decreased
expression of ganglioside biosynthetic enzymes (B3GALT4 and ST3GAL2), has been found in the SN
from PD patients [400,401]. Hence, most publications point towards increased gangliosides in plasma
of PD patients, but concomitant changes in ganglioside levels have not been observed in their brains.
Interestingly, GM1 supplementation seems to have a positive disease-modifying effect in PD
patients [402–407]. Also, increased GM1 levels are neuroprotective in MPTP-treated animals [408].
For example, GM1 can partially protect against 6-OHDA treatment [409] and aging-related DA
deficits [410] as well. However, studies on MPTP-treated non-human primates have shown that
a short treatment with GM1 does not lead to any improvement [411], while a chronic treatment does
have a positive effect [412], which might be restricted to the surviving DA neurons in the midbrain,
rather than due to the prevention of cell death [413]. Mechanistically, GM1 treatment increases DA
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innervation, dopamine synthesis, and TH expression following an MPTP lesion [414–423]. Moreover,
GM1 inhibits the inflammatory response triggered by 6-OHDA [424], protects against the toxic
intracellular GPR37 aggregates observed in parkinsonism [425] and is involved in the internalization
of α-synuclein into microglia [426]. Nonetheless, evidence for an α-synuclein-linked role of GM1 is
controversial: in one study it was claimed that GM1 may accelerate α-synuclein aggregation [427]
and the formation of proteinase-resistant α-synuclein [392], but other work demonstrated that it
induces alpha-helical structure and inhibits or eliminates α-synuclein fibril formation (depending
on the amount of GM1 present) [289,428]. It is also unclear whether membranes containing GM1
interact with α-synuclein [428,429]. Hence, GM1 is a promising candidate for PD treatment, but further
clarification of its specific effects on α-synuclein is urgently needed.
Only a limited number of studies have analyzed the role of gangliosides other than GM1 in animal
and cellular models. For instance, mice lacking GM2/GD2 synthase develop parkinsonism, which can
be partially rescued by administration of GM1 [400,430]. However, GM2 accumulation, as seen in Tay
Sachs and Sandhoff’s diseases, leads to α-synuclein aggregation [431]. Thus, both deficiency and excess
of GM2 may lead to PD-like pathology. Likewise, GM3 accelerates α-synuclein aggregation [427] and
regulates α-synuclein-induced channel formation in PC-containing membranes [301]. Furthermore,
deletion of GD3 synthase, which decreases production of the pro-apoptotic GD3 ganglioside, protects
against MPTP treatment in mice [432]. In contrast, ganglioside GT1b is neurotoxic in nigral
DA neurons by triggering nitric oxide release from activated microglia [433]. The gangliosides
GD3 and GT1b are unchanged and decreased in the SN of (male) PD patients, respectively [270].
Together, these results indicate that GM3, GD3, and GT1b play aggravating roles in PD pathology.
Finally, 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP, an inhibitor of glycosylceramide
synthase that decreases ganglioside content) enhances α-synuclein toxicity, which can be rescued by
ganglioside addition [434].
5.6. Sulfatides
Sulfatides, which are sulfated galactocerebrosides, form a group of lipids involved in protein
trafficking, immune responses and neural plasticity, among others [435]. Higher levels of sulfatides
have been detected in the plasma [385] and visual cortex [225] of PD patients, and in the SN of male
PD patients [270]. Arylsulfatase A, an enzyme that breaks down sulfatides, has been linked to PD
recurrence [436,437]. However, no changes or reductions in sulfatide levels have been described in
lipid rafts from the frontal cortex of PD patients [33] and in brain samples from PD patients [438],
respectively. Thus, most evidence points towards increased sulfatide levels in PD, although a number
of studies have not confirmed this finding, suggesting patient, technique and/or tissue-type differences
among the various investigations.
6. Sterols
Sterols are amphipathic lipids synthesized from acetyl-CoA via the β-hydroxy
β-methylglutaryl-CoA reductase pathway and containing a fused four-ring core structure
(Figure 6). Sterols are known to play a role in immune cell function [439], influence membrane fluidity
and permeability, and serve as signaling molecules and hormones [440], among others. Here we
will review the current findings on sterols in PD, more specifically cholesterol, its precursors, CE,
and oxysterols (Supplementary Materials Table S1).
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6.1. Cholesterol
6.1.1. Human Studies on Cholesterol
Cholesterol intake has been found to be negatively [29,441], positively [30,442], or not [31,443]
correlated with PD risk. A meta-analysis indicates a lack of association between cholesterol intake and
PD [444]. Lower plasma cholesterol has been associated with PD [229,232,445–447], and confirmed
by a meta-analysis [238], and higher plasma cholesterol levels have been linked to reduced PD
risk [235,448–452] and slower clinical progression of PD [453]. However, others, including a
meta-analysis [454], have found no association between plasma cholesterol levels and PD [230,455] or
PD risk [233,456]. Even higher plasma cholesterol levels in PD patients compared to controls [231,457]
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have been reported. The differential outcome of these studies could be attributed to factors such
as age and gender, among others, since lower plasma cholesterol levels have been reported in PD
male patients of more than 55 years compared to controls [458], a high total cholesterol baseline has
been associated with increased risk of PD in subjects of 25–54 years (but not in those above 55) [459],
and female PD patients seem to have higher cholesterol levels compared to male PD patients [460].
Thus, proper patient stratification is necessary to determine whether plasma cholesterol is associated
with PD, which would point towards defects in cholesterol metabolism.
In PD patients, no significant changes in cholesterol levels have been observed in the
putamen [383], SN [270] or frontal cortex lipid rafts [33], while elevated levels of cholesterol have been
found in the visual cortex [225]. Finally, decreased cholesterol biosynthesis has been described in
fibroblasts from PD patients [461]. The differences in these observations could be related to tissue or
brain-region specificities, technique sensitivity, and/or choice of patients. Thus, validation studies and
larger cohorts are needed to determine the relevance of cholesterol changes in PD patients and their
pathology. Additionally, some studies [13,462,463] have found an association between PD and a SNP
near the gene SREBF1, which encodes a transcription factor that regulates cholesterol biosynthesis,
although other studies could not confirm the findings [464].
6.1.2. Animal and Cellular Studies on Cholesterol
In animal and cell model studies, the link between PD and cholesterol has been demonstrated
multiple times. For example, the cholesterol biosynthetic pathway controls PRKN expression [465],
which in turn regulates fat (and cholesterol) uptake in PRKN mutant mice and human cells [466].
Additionally, DJ-1 KO mouse embryonic fibroblasts and astrocytes display lower cellular (but not
plasma [467]) cholesterol levels and impaired endocytosis [468], which can be rescued by increased
membrane cholesterol [469]. In contrast, GBA KO and PRKN KO cells have increased cholesterol
levels [470,471], and the N370S GBA mutation leads to cholesterol accumulation in lysosomes [472],
while LRRK2 KO rats have higher serum cholesterol levels [473]. Thus, cholesterol biosynthesis seems
to be impaired in PD, but the direction of the change differs among PD etiologies, which could explain
part of the variation observed in different studies with PD patients.
Increased cholesterol reduces cell death [474] and modulates presynaptic DA phenotype by
increasing TH and VMAT2 expression in SH-SY5Y cells [475] and enhancing ligand binding of DAT and
VMAT2 in the brains from rats and monkeys [476]. However, hypercholesterolemia seems to cause DA
neuronal loss and oxidative stress in the SN and the striatum, leading to motor impairment [477–479].
Together with the observation that cholesterol treatment of (MPP+-treated) SH-SY5Y cells reduces
their viability [480], this finding suggests that the effect of cholesterol levels on PD is dose dependent.
6.1.3. Alpha-Synuclein and Cholesterol
Alpha-synuclein interacts with cholesterol [481] and cholesterol-containing vesicles [482],
but it is unclear whether cholesterol facilitates the binding of α-synuclein to charge-neutral
membranes [483,484]. Alpha-synuclein-cholesterol interaction seems to be associated with α-synuclein
accumulation [474,485] and aggregation [486] and is a determining factor in α-synuclein’s ability
to form pores [487,488]. Accordingly, reducing cholesterol levels leads to decreased α-synuclein
accumulation and damage in the synapse [489–491]. Hence, high levels of cholesterol aggravate
α-synuclein-associated pathology. Furthermore, α-synuclein potentiates cholesterol efflux [492],
antagonizes cholesterol in lipid rafts [493], and enhances production of oxidative cholesterol
metabolites [494]. Finally, A53T-α-synuclein-overexpressing mice have increased levels of serum
cholesterol [239], while WT-α-synuclein-overexpressing mice have upregulation of genes involved in
cholesterol biosynthesis in DA neurons from the SN [495], indicating a tight reciprocal relationship
between α-synuclein and cholesterol metabolism.
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6.1.4. Statins
Statins are cholesterol-lowering drugs that have been described to decrease [496–501] or not
affect [502–504] PD risk. Interestingly, lipophilic, but not hydrophilic, statins increase PD risk [505].
In the current discussion on the contradictory findings regarding the effects of statins not enough
attention is paid to confounding factors such as statin indication, statin-type effects or immortal time
bias (span of cohort follow-up during which the outcome under study cannot occur), and healthy
user effects [506]. In animal and cellular models, atorvastatin pretreatment seems to prevent early
effects of MPTP administration in rats [507], and lovastatin has neuroprotective effects against MPP+
and 6-OHDA [474,508] and ameliorates α-synuclein accumulation [509,510]. Similarly, simvastatin is
neuroprotective against 6-OHDA and MPTP treatments [511–514] and increases dopamine content
in the striatum [515]. However, negative effects of simvastatin and atorvastatin on MPP+-mediated
toxicity have also been reported [516], which could be explained by the fact that statin lactones, one of
the statin metabolites, are able to inhibit mitochondrial complex III [517], potentiating MPP+ toxicity.
6.2. Cholesterol Precursors
In PD patients, the cholesterol-synthesizing enzymes isopentenyl diphosphate isomerases 1 and
2 have been observed in LB from the SN of PD patients [518]. The natural cholesterol intermediate
squalene seems to prevent toxicity in the striatum of 6-OHDA-treated mice [519], whereas α-synuclein
accumulation enhances squalene production [242], which could be a cellular response to oxidative
damage. A derivative of squalene, squalane, exacerbates 6-OHDA toxicity [519]. The naturally
occurring cholesterol precursor lanosterol induces mitochondrial uncoupling and protects DA neurons
from cell death in the nigrostriatal region of MPTP-treated mice [520]. Thus, cholesterol precursors
seem to have a protective role in PD. Interestingly, inhibitors of both geranylgeranyl transferase (GGTI)
and farnesyl transferase (FTI), enzymes that transfer the prenyl group geranylgeranyl or farnesyl to
proteins, protect nigrostriatal neurons in MPTP-intoxicated mice [521].
6.3. CEs
The esters between cholesterol and fatty acids, CEs, are synthesized from excess cholesterol
in the cytosol by the enzyme acetyl-coA acetyltransferase 1, a process that can be reversed by the
enzyme cholesteryl ester hydrolase. In PD patients, reduced cholesterol esterifying activity has
been detected in fibroblasts [461] and CE 20:5 is reduced in their visual cortex [222]. Interestingly,
in C. elegans the ortholog of neutral cholesteryl ester hydrolase 1 attenuates α-synuclein neurotoxicity
when sufficient CE is present, while knockdown leads to neurodegeneration [522]. However, GBA KO
cells have increased levels of CE 15:1, 22:6, and 24:1 [470], which could reflect either a protective or a
pathological mechanism.
6.4. Oxysterols
The products of cholesterol oxidation, 7beta- and 27-hydroxycholesterol, and 7-ketocholesterol,
are elevated in plasma from PD patients [162]. Additionally, 27-hydroxycholesterol CSF levels are
increased in a subgroup of PD patients [523] Moreover, increased cholesterol lipid hydroperoxides
have been observed in the SN of PD patients [524]. The CSF levels of 24-hydroxycholesterol appear to
be correlated with PD duration [523], but higher levels have also been observed in early stage PD [525].
Conversely, 24-hydroxycholesterol esters are reduced in plasma from PD patients [526]. Of note, TH
levels are increased by 24-hydroxycholesterol [527], while 27-hydroxycholesterol seems to reduce TH
expression and increases α-synuclein levels [527–530]. An unexpected finding was that both 24- and
27-hydroxycholesterol seem to protect against staurosporine-induced cell death [531]. Interestingly,
oxysterols, and more specifically 24(S),25-epoxycholesterol, increase DA neuronal differentiation via
liver X receptors in both mouse and human embryonic stem cells [532,533].
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7. Lipoproteins
Lipoproteins transport triglycerides and cholesteryl esters. Together, these lipids form the core
of the lipoprotein, which is further surrounded by glycerophospholipids and free cholesterol [534].
Lipoproteins are classified according to their density, and thus their composition, as high-density
lipoproteins (HDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL) or VLDL.
Here, we will specifically review the current findings concerning HDL, LDL and VLDL (Supplementary
Table S1).
7.1. HDL
The assembly complex HDL is composed of proteins (around 40%, mainly apolipoprotein A1
(ApoA1), but also apolipoprotein C (ApoC), apolipoprotein E (ApoE), and apolipoprotein J (ApoJ))
and lipids (including around 30% of glycerophospholipids, 25% of cholesterol/CE, and 5% of TAG).
The main biological role of HDL is in cargo transport, in particular of lipids and proteins, but it is now
also known to bring miRNAs to recipient cells [535]. Lower plasma HDL and ApoA1 levels have been
associated with earlier PD onset [536] and higher PD risk [237,537–539], and HDL levels are positively
correlated with disease duration [540]. Plasma levels of HDL-cholesterol are lower [229,385,541] or not
different [230,233,446,447,457] in PD patients compared to controls. This controversial relationship is
complex, as both sex [460] and APOE polymorphisms [231] seem to affect HDL-cholesterol levels in
PD patients.
7.2. LDL
About 20% of LDL consists of proteins (mainly apolipoprotein B (ApoB)) and the remainder
consists of lipids (including about 22% of glycerophospholipids, 50% of cholesterol/CE, and 8% of
TAG). High LDL-cholesterol levels in plasma are protective for PD and associated with preserved
executive and fine motor functions in PD [452,455,457,542], while lower LDL-cholesterol levels are
associated with higher PD risk [229,445–447,500,543,544]. One study reported that plasma LDL
levels are not different between PD patients and controls [237]. A number of other studies have
reported no difference in baseline LDL-cholesterol [230,497], and two meta-analyses have found no
association [238,496]. Furthermore, in contrast to HDL, LDL-cholesterol levels do not differ between
male and female PD patients [460,540]. However, one study reported increased LDL-cholesterol levels
in PD patients compared to controls [231]. Interestingly, compared to controls PD patients seem to have
higher levels of oxidized LDL [545], which is able to enter neuronal cells and elicit neurotoxicity [546].
Finally, male DJ-1 KO mice have higher LDL-cholesterol levels in serum, which could be due to the
fact that the LDLR is a transcriptional target of DJ-1 [467].
7.3. VLDL
Very low-density lipoproteins are mainly composed of lipids (including around 15% of
glycerophospholipids, 20% of cholesterol/CE, and 60% of TAG) and only minor amounts of protein
(around 5%, mainly ApoB and ApoC). Parkinson’s disease patients appear to have lower levels of both
VLDL [230] and VLDL-cholesterol [231] than controls, but the role of VLDL in PD remains unclear.
8. The Cellular Lipidome
Above we have given an overview of the changes in lipid composition that have been observed
in multiple studies involving PD patients, and animal and cellular PD models. The question arises
what the significance of such changes is from a biological point of view. In mammalian cells, about
5% of the genes are involved in the generation and transport of an estimate of 10,000 individual lipid
species [547,548], which have structural [549], signaling [549,550], and energy storage [17,18] roles.
More specifically, above-mentioned molecules such as glycerophospholipids, sphingolipids, and sterols
represent the main components of the cell’s plasma and mitochondrial membranes, endoplasmic
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reticulum, the Golgi complex, and endosomes. In a dynamic manner, lipid composition defines
organelle identity [547], controls the recruitment of proteins, and lipid bilayer properties, such as
thickness, elastic compression, and intrinsic curvature, can be an allosteric regulator of membrane
protein function [551]. Alterations in membranes thus dynamically control important processes such as
(synaptic) vesicle trafficking, endocytosis-exocytosis [552] or α-synuclein aggregation [553], processes
that have already been associated with PD [554–556].
Lipids also play an important role in intracellular and intercellular signaling in the brain by
direct interaction with receptors and other signal-transducing proteins [549,550] that regulate integral
physiological processes linked to PD. For example, PUFA are involved in inflammation, neurogenesis,
and neuroprotection [56]. Endocannabinoids are lipid-based retrograde neurotransmitters that
modulate synaptic plasticity [557], and LPA modulates processes like proliferation, survival and
migration [249]. Additionally, although most energy consumed by brain cells comes from glucose,
lipids have been suggested to provide up to 20% of the total energy consumption of the adult
brain [549,558,559]. Therefore, changes in lipid composition or content, such as the ones that have been
described here for PD, can have vast consequences for key processes in the maintenance of normal
neuronal and brain function. However, unlike what holds for genes and proteins, most lipid species
cannot be associated with specific functions: their role is dictated by the concentration and location
of individual lipid species, and, most importantly, by their interaction with other lipid species. Since
most of the available information is a description of changes in lipid concentration, firm conclusions
regarding the effects of these changes are hard to draw.
This lack of precise knowledge regarding the (patho)biological significance of lipidome
abnormalities is predominantly caused by the fact that lipids form a vast and enormously complex
group of biomolecules. This creates two major challenges. First, it is currently very difficult—if not
impossible—to characterize all lipids present in the lipidome of a sample, due to limitations in the
separation methods. This precludes simultaneous analysis of all lipid classes, which is especially
hindered by the presence of isomeric (i.e., same mass) lipids. Second, no methodology is currently
available to accurately determine the concentrations of the various lipid species [560]. This lack of
information hampers the interpretation of lipidomic studies and the creation of reliable databases that,
on its turn, impedes the identification of pathways in which a combination of lipid species plays a
role [561].
As mentioned, not only their composition in the lipidome but also the tissue distribution and
intracellular localization of individual lipids are crucial for their function, which makes it of great
importance to develop techniques to identify and quantify lipids at the single-cell level and with the
spatial organization of the cell still intact. These developments will help to elucidate the interplay of
different lipid species in a time- and location-dependent manner both in health and disease. Indeed,
it would allow us to obtain more information about (i) the lipidomes of various cell types, which are
now identified in growing numbers within different tissues and organs by RNAseq [562], and (ii) the
dynamic changes in lipidome composition that are associated with disease progression. Unfortunately,
proper sample preparation, even more than the detection limits for lipids in mass-spectrometry,
currently forms the biggest barrier to develop effective single-cell lipidomics [563]. Moreover,
the interplay between lipids and other biomolecules necessitates the integration of lipidomics with
other omics strategies [564].
It is also important to note that the lipidome composition is not only defined by the activity
of genes involved in lipid metabolism, but also strongly depends on exogenous factors. These
include (1) the direct dietary intake of lipids and lipid precursors from food, (2) life-style factors, i.e.,
exercise, sleep patterns, and intrinsic and extrinsic motivation factors that determine the choice of
food composition, and (3) the effects of drugs that affect metabolism or cell behavior. For example,
accumulating evidence suggests that tight bidirectional interactions exist between dietary lipids and
composition and structure of the gastrointestinal tract microbiota [565–567]. This could be especially
relevant for PD, since dysbiosis (i.e., the change in microbiota structure relative to that found in healthy
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individuals [568]), has been repeatedly observed in PD patients [569–574] from early stages of the
disease onwards [575].
Filling in the current gaps in lipidomics technology and knowledge is crucial to exploit its potential
to help us further understand the molecular mechanisms underlying PD, better define its stages and
classification, and identify biomarkers, create dietary interventions, or perform compound screening,
preclinical testing and monitoring of drug responses [576,577].
9. Conclusions
From this review, it is clear that a strong correlation exists between PD and abnormalities
in lipid metabolism. More specifically, there is an association between PD and the levels of
fatty acyls (SFA, MUFA, PUFA, a number of eicosanoids, and acylcarnitine), glycerolipids (MAG,
DAG, and TAG), glycerophospholipids (PA, LPA, PE, PS, PC, LPC, PI, PIPx, PG, and CL),
sphingolipids (sphingosine(-1P), ceramide, SM, cerebrosides, gangliosides, and sulfatides), sterols
(cholesterol precursors, cholesterol, CE, and oxysterols) and lipoproteins (HDL, LDL, and VLDL).
Furthermore, there is a conspicuous relationship between the folding, aggregation, and distribution
of α-synuclein and the lipids that drive some of the neuropathological features of PD. Yet, it is
presently unclear whether links exist between PD and some eicosanoids (eoxins, thromboxanes,
oxoeicoanoids, hepoxilins, lipoxins, and epoxyeiconsatetraenoic acid), glycerophospholipids (lysoPE,
lysoPS, lysoPI, lysoPG, lysoCL, and Bis(monoacylglycero)phosphate), sphingolipids (globosides),
and lipoproteins (IDL).
One of the main concerns regarding the findings summarized in this review is that most lipid
classes have not been consistently found to be associated with PD. Variables such as sex, age, PD
etiology, specific DNA polymorphisms or the microbiome may have influenced the findings. Thus,
proper stratification of PD patients is necessary to understand the biological implications of the lipid
changes observed. Additionally, more accurate description of the lipid profiles of plasma, CSF and/or
fibroblasts from PD patients will help to classify the patients more accurately.
A further concern is that most studies have focused on plasma levels of lipids, but these may
not correlate with their brain levels, e.g., levels of ganglioside species are increased in plasma but
not in brains of PD patients [270,385]. Thus, CSF (and brain) lipidomes of PD patients have to be
determined to get insight into the actual pathological lipid composition and processes. Moreover,
it is often unclear whether the changes in the levels of lipid species reflect a pathological or rather a
compensatory mechanism. Finally, studies on cellular and animal PD models do not always show the
same directionality of lipid level changes as found in studies on PD patients.
In conclusion, ample evidence for a central role of lipids in PD is available, but current data yield a
picture that is still too fragmented. This hinders the unraveling of the specific pathological mechanisms
in which lipids are involved. Technological advances to better characterize the lipidome and explore
the functions of specific lipid species, together with additional studies on CSF and/or brain tissue
from PD patients are now urgently needed to further our understanding of the pathobiology of the
relationship between PD and lipids and will help us to identify biomarkers and druggable targets for
the development of disease-modifying therapies for this devastating neurodegenerative disease.
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